Real-time Estimate
Cboe BZX
14:48:02 2024-04-29 EDT
|
5-day change
|
1st Jan Change
|
1.065
USD
|
+4.41%
|
|
+0.47%
|
-60.99%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,641
|
7,350
|
531.7
|
717.4
|
238.8
|
90.32
|
-
|
-
|
Enterprise Value (EV)
1 |
4,602
|
6,691
|
107.5
|
437.6
|
68.02
|
8.051
|
-103.1
|
-31.02
|
P/E ratio
|
-
|
-45.2
x
|
-1.95
x
|
-1.66
x
|
-1.28
x
|
-0.86
x
|
-1.36
x
|
-1.44
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-51.2
x
|
-43
x
|
-0.4
x
|
-1.39
x
|
-
|
-0.07
x
|
1.17
x
|
0.35
x
|
EV / FCF
|
-
|
-58,413,250
x
|
-445,880
x
|
-
|
-
|
-
|
1,055,370
x
|
310,241
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
0%
|
0%
|
Price to Book
|
-
|
-
|
1.18
x
|
1.72
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
48,666
|
52,503
|
54,313
|
85,204
|
87,476
|
88,544
|
-
|
-
|
Reference price
2 |
95.36
|
140.0
|
9.790
|
8.420
|
2.730
|
1.020
|
1.020
|
1.020
|
Announcement Date
|
20-02-25
|
21-03-01
|
22-03-01
|
23-03-06
|
24-03-14
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-89.91
|
-155.5
|
-269.2
|
-315.4
|
-
|
-118.4
|
-88.18
|
-88.2
|
EBIT
1 |
-91.42
|
-157.1
|
-271.5
|
-322.4
|
-196.1
|
-111.3
|
-80.91
|
-92.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-269.9
|
-320
|
-185.7
|
-93.72
|
-76.28
|
-91.34
|
Net income
1 |
-
|
-153.5
|
-269.9
|
-320
|
-185.7
|
-105.9
|
-75.84
|
-87.97
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-3.100
|
-5.010
|
-5.060
|
-2.140
|
-1.191
|
-0.7500
|
-0.7100
|
Free Cash Flow
|
-
|
-114.6
|
-241.1
|
-
|
-
|
-
|
-97.7
|
-100
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-25
|
21-03-01
|
22-03-01
|
23-03-06
|
24-03-14
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-62.24
|
-94.9
|
-193.5
|
-46.99
|
-30.13
|
-44.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-62.62
|
-96.08
|
-195.7
|
-49.12
|
-31.44
|
-46.22
|
-45.05
|
-37.82
|
-48.21
|
-64.98
|
-60.21
|
-31.63
|
-20.58
|
-37.15
|
-16.63
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-62.73
|
-94.36
|
-197
|
-49.1
|
-30.84
|
-42.99
|
-42.4
|
-35.12
|
-45.63
|
-62.55
|
-35.47
|
-25.32
|
-19.51
|
-18.97
|
-16.63
|
Net income
1 |
-62.73
|
-94.36
|
-197
|
-49.1
|
-30.84
|
-42.99
|
-42.4
|
-35.12
|
-45.63
|
-62.55
|
-57.43
|
-29.89
|
-19.28
|
-36.05
|
-16.63
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.160
|
-1.730
|
-3.600
|
-0.9000
|
-0.5300
|
-0.5000
|
-0.4900
|
-0.4100
|
-0.5200
|
-0.7100
|
-0.4371
|
-0.3357
|
-0.2143
|
-0.2029
|
-0.2067
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-08
|
22-03-01
|
22-05-06
|
22-08-04
|
22-11-07
|
23-03-06
|
23-05-09
|
23-08-09
|
23-11-13
|
24-03-14
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
38.4
|
659
|
424
|
280
|
171
|
82.3
|
193
|
121
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-115
|
-241
|
-
|
-
|
-
|
-97.7
|
-100
|
ROE (net income / shareholders' equity)
|
-
|
-26.7%
|
-49.1%
|
-84.7%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
8.280
|
4.910
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-3.860
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.63
|
33.2
|
8.33
|
-
|
-
|
1
|
1
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-25
|
21-03-01
|
22-03-01
|
23-03-06
|
24-03-14
|
-
|
-
|
-
|
Last Close Price
1.02
USD Average target price
2.9
USD Spread / Average Target +184.31% Consensus |
1st Jan change
|
Capi.
|
---|
| -60.99% | 90.32M | | -2.74% | 103B | | +1.53% | 95.28B | | +1.46% | 22.15B | | -15.61% | 21.02B | | -8.58% | 18.15B | | -38.74% | 16.73B | | -12.90% | 16.05B | | +5.36% | 13.68B | | +33.69% | 12.17B |
Bio Therapeutic Drugs
|